OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Manufacturers face the challenge of meeting growing demand for personalized biopharmaceuticals.
Despite many development challenges, stable producer cell lines show real promise.
CPC presents a green alternative to chromatography that supports sustainable operations.
Experts outline the benefits of single-use consumables relative to traditional approaches.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
September 29, 2023
Under the partnership, Sartorius will leverage SPARTA Biodiscovery’s technology to accelerate development of nanoparticles used for drug delivery.
The contract is part of US Department of Health and Human Services’ ‘Project NextGen’ initiative, aimed at pushing forward new and stronger COVID-19 vaccines and therapies.
Drug efficacy, reputation, and financial return are all on the line when it comes to fill/finish.
A survey was conducted to examine the adoption of machine learning and artificial intelligence in the bio/pharma manufacturing industry.
Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.
Using a systematic approach and achieving run-to-run consistency are essential.
September 28, 2023
The innovation of affinity ligands must take stability into consideration for present and future purification applications.
The steady rise in popularity of gene therapies and other biologics is the underlying reason for the growing importance of aseptic manufacturing processes in the biopharmaceutical industry.
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.
Glycosylation analysis can provide a deep and nuanced understanding of immune cell phenotype and function.
The European Commission has granted approval for Tyruko (natalizumab), a biosimilar developed by Polpharma Biologics for treating multiple sclerosis.
The agency will be reorganizing field force and compliance functions.